Else Nutrition Applauds Pivotal U.S. Legislative Support for Plant-Based, Non-Soy, Non-Dairy Infant Formula Innovation
Else Nutrition (OTCQX: BABYF) welcomes a significant legislative development as the U.S. House Appropriations Committee passes the FY2026 Agriculture and FDA Appropriations Bill. The legislation specifically directs the FDA to streamline approval pathways for plant-based, non-soy, and non-dairy infant formulas.
The bill includes crucial language supporting alternative infant formula access and calls for formal regulatory guidance for non-dairy, non-soy plant-based formulas. This initiative is part of Operation Stork Speed, the Administration's effort to accelerate innovation in infant formula. While the legislation still needs full House approval, it represents a significant step toward expanding the U.S. infant formula market and potentially expediting Else Nutrition's market access.
Else Nutrition (OTCQX: BABYF) accoglie con favore un importante sviluppo legislativo, poich茅 la Commissione per le Assegnazioni della Camera degli Stati Uniti ha approvato il disegno di legge sulle assegnazioni agricole e della FDA per l'anno fiscale 2026. La normativa indirizza specificamente la FDA a semplificare le procedure di approvazione per le formule infantili a base vegetale, non a base di soia e senza latticini.
Il disegno di legge include un linguaggio fondamentale a sostegno dell'accesso a formule alternative per l'infanzia e richiede una guida regolatoria formale per le formule vegetali non lattiero-casearie e non a base di soia. Questa iniziativa fa parte di Operation Stork Speed, lo sforzo dell'Amministrazione per accelerare l'innovazione nelle formule per l'infanzia. Sebbene la normativa debba ancora ricevere l'approvazione completa della Camera, rappresenta un passo importante verso l'espansione del mercato statunitense delle formule per l'infanzia e potrebbe accelerare l'accesso al mercato di Else Nutrition.
Else Nutrition (OTCQX: BABYF) celebra un importante avance legislativo tras la aprobaci贸n por parte del Comit茅 de Asignaciones de la C谩mara de Representantes de EE.UU. del proyecto de ley de asignaciones para Agricultura y la FDA del a帽o fiscal 2026. La legislaci贸n dirige espec铆ficamente a la FDA a simplificar las v铆as de aprobaci贸n para f贸rmulas infantiles a base de plantas, sin soja y sin l谩cteos.
El proyecto de ley incluye un lenguaje clave que apoya el acceso a f贸rmulas infantiles alternativas y solicita una gu铆a regulatoria formal para f贸rmulas vegetales no l谩cteas y sin soja. Esta iniciativa es parte de Operation Stork Speed, el esfuerzo de la Administraci贸n para acelerar la innovaci贸n en f贸rmulas infantiles. Aunque la legislaci贸n a煤n requiere la aprobaci贸n total de la C谩mara, representa un avance significativo para expandir el mercado estadounidense de f贸rmulas infantiles y potencialmente acelerar el acceso al mercado de Else Nutrition.
Else Nutrition (OTCQX: BABYF)電� 氙戈淡 頃橃洂 靹胳稖鞙勳洂須岅皜 2026 須岅硠鞐半弰 雴嶌梾 氚� FDA 靹胳稖 氩曥晥鞚� 韱店臣鞁滍偍 欷戩殧頃� 鞛呺矔 氚滌爠鞚� 頇橃榿頃╇媹雼�. 鞚� 氩曥晥鞚� 韸鬼瀳 FDA臧� 鞁濍靹�, 牍勲寑霊�, 氍挫湢鞎勱赴 攵勳湢 鞀轨澑 鞝堨皑毳� 臧勳唽頇旐晿霃勲 歆�鞁�頃橁碃 鞛堨姷雼堧嫟.
氩曥晥鞐愲姅 雽�觳� 鞙犾晞鞖� 臁办牅攵勳湢 鞝戧芳鞚� 歆�鞗愴晿電� 欷戩殧頃� 臁绊暛鞚� 韽暔霅橃柎 鞛堨溂氅�, 牍勳湢鞝滍拡 氚� 牍勲寑霊� 鞁濍靹� 臁办牅攵勳湢鞐� 雽�頃� 瓿奠嫕 攴滌牅 歆�旃� 毵堧牗鞚� 鞖旉惮頃╇媹雼�. 鞚� 鞚措媹靺旐嫲敫岆姅 鞙犾晞鞖� 臁办牅攵勳湢 順侅嫚 臧�靻嶍檾毳� 鞙勴暅 頄夓爼攵�鞚� 雲鸽牓鞚� Operation Stork Speed鞚� 鞚柬櫂鞛呺媹雼�. 氩曥晥鞚� 鞎勳 頃橃洂 鞝勳泊 鞀轨澑鞚� 氚涭晞鞎� 頃橃毵�, 氙戈淡 鞙犾晞鞖� 臁办牅攵勳湢 鞁滌灔 頇曤寑鞕� Else Nutrition鞚� 鞁滌灔 歆勳瀰 臧�靻嶍檾鞐� 欷戩殧頃� 歆勳爠鞚� 鞚橂頃╇媹雼�.
Else Nutrition (OTCQX: BABYF) se f茅licite d'une avanc茅e l茅gislative majeure alors que le Comit茅 des cr茅dits de la Chambre des repr茅sentants des 脡tats-Unis adopte le projet de loi sur les cr茅dits agricoles et de la FDA pour l'exercice 2026. La l茅gislation ordonne sp茅cifiquement 脿 la FDA de simplifier les voies d'approbation pour les formules infantiles 脿 base de plantes, sans soja et sans produits laitiers.
Le projet de loi inclut un langage cl茅 soutenant l'acc猫s aux formules infantiles alternatives et demande une orientation r茅glementaire formelle pour les formules v茅g茅tales sans produits laitiers ni soja. Cette initiative fait partie de Operation Stork Speed, l'effort de l'administration pour acc茅l茅rer l'innovation dans les formules infantiles. Bien que la l茅gislation doive encore obtenir l'approbation compl猫te de la Chambre, elle repr茅sente une 茅tape importante vers l'expansion du march茅 am茅ricain des formules infantiles et pourrait potentiellement acc茅l茅rer l'acc猫s au march茅 d'Else Nutrition.
Else Nutrition (OTCQX: BABYF) begr眉脽t eine bedeutende gesetzgeberische Entwicklung, da der Haushaltsausschuss des US-Repr盲sentantenhauses den Haushaltsgesetzesentwurf f眉r Landwirtschaft und FDA f眉r das Gesch盲ftsjahr 2026 verabschiedet hat. Das Gesetz weist die FDA ausdr眉cklich an, Zulassungsverfahren f眉r pflanzenbasierte, soja- und milchfreie S盲uglingsnahrungen zu vereinfachen.
Der Gesetzentwurf enth盲lt wesentliche Formulierungen zur Unterst眉tzung des Zugangs zu alternativen S盲uglingsnahrungen und fordert eine formelle regulatorische Leitlinie f眉r milchfreie, soja- und pflanzenbasierte Formeln. Diese Initiative ist Teil von Operation Stork Speed, dem Bem眉hen der Regierung, Innovationen bei S盲uglingsnahrung zu beschleunigen. Obwohl das Gesetz noch die vollst盲ndige Zustimmung des Repr盲sentantenhauses ben枚tigt, stellt es einen bedeutenden Schritt zur Erweiterung des US-Marktes f眉r S盲uglingsnahrung dar und k枚nnte Else Nutrition den Marktzugang erleichtern.
- Legislative support for streamlining FDA approval of plant-based infant formulas
- Potential acceleration of market access for Else's products through Operation Stork Speed initiative
- Congressional recognition of need for alternative infant formula options
- Improved regulatory pathway clarity for non-dairy, non-soy formulations
- Full House approval still pending
- Report language is non-binding on FDA actions
- Regulatory implementation timeline remains uncertain
House Appropriations Committee Champions Greater Nutritional Choice聽and Market Access for
FDA Directed to Streamline Approval Pathways for Plant-Based Infant Formulas, Positioning Else Nutrition to Capitalize on Legislative聽Momentum and Rising Consumer Demand
The accompanying report directs the
"This marks聽a turning point聽for American families and for Else Nutrition,"聽said Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition. "For too long, parents聽have had to choose between聽limited formula options that may not meet聽their child's聽needs. This聽legislative milestone signals that change is聽coming鈥攖oward a more inclusive and diversified infant formula landscape. We commend Congress for recognizing this urgent need and taking action that we believe will benefit families for generations to come."
Although these types of advanced formulas have gained traction in global markets, regulatory delays have historically constrained innovation in the U.S. market. The recently advanced legislative language is a strong signal to the FDA to establish clear, actionable guidance that can accelerate the availability of safe, effective, and scientifically backed alternatives.
The report also highlights the Operation Stork Speed initiative, part of the Administration's broader effort to fast-track innovation in the infant formula space. By elevating plant-based, non-dairy, non-soy formulations as a key component of this initiative, the legislation reinforces the national commitment to nutritional accessibility and product diversity.
While additional legislative steps remain鈥攊ncluding passage by the full House鈥攖he inclusion of this language in the committee's final report is a powerful indication of Congressional momentum. Though report language is non-binding, it frequently shapes agency priorities, resource allocation, and the pace at which new regulatory frameworks are developed.
For Else Nutrition, the implications are clear: the path to broader U.S. market access is becoming more defined.
"This is the clearest signal yet that
DISCLAIMERS
This grassroots lobbying effort is a statement of issue advocacy and does not require disclosure under the Lobbying Disclosure Act. This is not an electioneering statement, and this message has not been coordinated with any political parties or candidates. This message is paid for by Else Nutrition and is intended for only a "restricted class" of stockholders and administrators of the company. Whereas this is an instance of grassroots lobbying, Else Nutrition's engaged lobbying principals file disclosures required under the Lobbying Disclosure Act for direct lobbying services on behalf of the company.
About Else Nutrition Holdings Inc.
Else Nutrition Holdings Inc. (TSX: BABY, OTCQX: BABYF, FSE: 0YL) is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and Plant-Based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, Plant-Based, non-soy formula is a clean-ingredient alternative to dairy-based formulas. Since launching its Plant-Based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of powerful testimonials and reviews from parents, gained national retailer support, and achieved rapid sales growth.
Awards and Recognition:
- "2017 Best Health and Diet Solutions" award at
Milan 's Global Food Innovation Summit - #1 Best Seller on Amazon in the Fall of 2020 in the New Baby & Toddler Formula Category
- "Best Dairy Alternative" Award 2021 at World Plant-Based Expo
- Nexty Award Finalist at Expo West 2022 in the Plant-Based lifestyle category
- During September 2022, Else Super Cereal reached the #1 Best Seller in Baby Cereal across all brands on Amazon
TSX
Neither the TSX nor its regulation services provider (as that term is defined in the policies of the TSX) accept responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will" or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the company's financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs, and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID-19 and that the manufacturing, broker, and supply logistic agreement with the company does not terminate. Actual results may differ from the estimates, beliefs, and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
View original content to download multimedia:
SOURCE Else Nutrition Holdings Inc.
FAQ
What is the significance of the U.S. House Appropriations Committee's decision for Else Nutrition (BABYF)?
What is Operation Stork Speed and how does it affect Else Nutrition (BABYF)?
What are the next steps for the FY2026 Agriculture and FDA Appropriations Bill affecting Else Nutrition?
How will the new legislation impact the U.S. infant formula market?
What types of infant formulas will benefit from this new legislative support?
